AstraZeneca Pharma India (AZPIL), incorporated on July 11, 1979, is a global, science-led, patient-focused pharmaceutical company. The company is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom. The company is dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. The company’s focus areas in India include BioPharmaceuticals, Oncology, and Rare Diseases, which are pivotal to its Growth Through Innovation strategy.

The company operates with purpose and integrity, using science, innovation, and global reach to deliver life-changing medicines. It is committed to equitable access, healthier communities, and environmental responsibility across its value chain. By embedding sustainability at its core and following the science, the company strives to improve health outcomes and create lasting value for patients, society, and the planet.

Rated as one of the finest in South East Asia, AstraZeneca’s Indian manufacturing facility has a sophisticated production facility designed to meet the most stringent international standards, conforming to WHO cGMP (current Good Manufacturing Practices) norms. The facility is an ISO 14001 certified company and has a full-fledged environment management system in place.

The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products. Guided by the values & processes of AstraZeneca, international guidelines & local regulatory framework the team collaborates with top-notch healthcare practitioners and medical institutes to bring AstraZeneca’s medicines as quickly, safely and efficiently as possible.

Business area of the company

AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products.

Core Therapy Areas

• Oncology
• BioPharmaceuticals
• Rare Disease

Milestones and achievements

• 1979: Formation of AstraIDL, promoted by Astra Pharmaceuticals AB Sweden and IDL Chemicals Hyderabad.
• 1982: Astra-IDL listed on the Bombay Stock Exchange (BSE) - 5.6 times oversubscription.
• 1982: Foundation stone of the Yelahanka site laid by the Prime Minister of Sweden.
• 1988: Started maternal health product division.
• 1989: Launched Restomycin, Bromenyl, Febrafen and Prostodin.
• 1996: Inauguration of R&D Centre in Bengaluru.
• 1998: Astra IDL touched its first Rs 100 crore mark with a revenue of Rs 102.47 crore.
• 1999: AstraZeneca formed by the global merger of Astra and Zeneca.
• 2001: AstraZeneca announced it had completed a transaction to buy a controlling stake in the joint venture company Astra-IDL and renamed it AstraZeneca Pharma India Ltd.
• 2001: Introduction of Seloken XL. Partnership with Bristol-Myers Squibb (BMS).
• 2003: Launch of Seloken XL.
• 2010: Launch of Young Health Programme (YHP) in India.
• 2011: AstraZeneca crosses Rs 500 crore turnover mark.
• 2012: Launch of Brilinta.
• 2014: Move of commercial operations and clinical operations to Manyata Tech Park, Bengaluru.
• 2014: Launch of new tablet production facility.
• 2014: Launch of Global Technology Chennai (GTC).
• 2015: Launch of Forxiga.
• 2016: AZ IT’s three-year IT Transformation Journey completed successfully in 2016.
• 2017: Launch of Tagrisso.
• 2017: Launch of GBS Global Commercial Operations India.
• 2018: Launch of the first Metabolic Centre of Excellence.
• 2019: 40th anniversary of AstraZeneca and launch of India- Sweden Healthcare Innovation Centre.
• 2021: AstraZeneca global’s COVID-19 vaccine saved more than six million lives worldwide. Around 3 billion vaccine doses supplied worldwide, with significant contributions to lowand middle-income countries.
• 2021: Establishing and expanding the CDI footprint in India: launched a clinical data and insights division in India to further strengthen its global presence, and for the management of data-related aspects of its clinical trials.
• 2022: Rebranded Global Technology Centre to Global Innovation Technology Centre (GITC).
• 2022: Established Clinical Regulatory Writing (CReW) to drive strategic medical writing excellence across R&D.
• 2023: Launched its India Bold Ambition aligning with its Growth Through Innovation Strategy.
• 2023: MoU with Government of Karnataka to deploy Artificial Intelligence (AI) based Lung Cancer screening technology in 19 district hospitals.
• 2023: Signed MoU with Roche Diagnostics India to improve diagnostics for breast cancer patients.
• 2023: Launched the global AZ Forest initiative in India in the state of Meghalaya.
• 2023: Expanded portfolio with Rare Disease Business Unit (BU) with the launch of Selumetinib.
• 2023: Expanded its R&D division in Bengaluru.
• 2024: MoU with Government of Goa to accelerate the detection of lung cancer in the state.
• 2024: AstraZeneca celebrates 45 years in India. Continued focus on accelerating the delivery of life-changing medicines and operating sustainably.
• 2024: AstraZeneca celebrates 10 years of GITC, India.
• 2024: AstraZeneca Pharma India and Mankind Pharma entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
• 2025: AstraZeneca Pharma India (AstraZeneca) entered into distribution services agreement with Sun Pharmaceutical Industries (Sun Pharma) for the distribution of Sodium Zirconium Cyclosilicate (SZC) powder for oral suspension 5 g in India.
• 2026: AstraZeneca Pharma India received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Brand Name: Imfinzi) for an additional indication.